A First‐in‐Human Phase I Study of GC1118, a Novel Anti‐Epidermal Growth Factor Receptor Antibody, in Patients with Advanced Solid Tumors

LESSONS LEARNED. GC1118 is a novel fully human anti‐epidermal growth factor receptor (EGFR) antibody with unique binding epitopes and different ligand‐binding inhibitory activity compared with cetuximab or panitumumab. GC1118 showed promising antitumor activity, especially in patients with colorecta...

Descripción completa

Detalles Bibliográficos
Autores principales: Oh, Do‐Youn, Lee, Keun‐Wook, Han, Sae‐Won, Kim, Jin Won, Shin, Jung‐Won, Jo, Seong‐Jin, Won, Jonghwa, Hahn, Seokyung, Lee, Howard, Kim, Woo Ho, Bang, Yung‐Jue
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2019
Materias:
Clinical Trial Results
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6693725/
https://www.ncbi.nlm.nih.gov/pubmed/31164456
http://dx.doi.org/10.1634/theoncologist.2019-0294

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6693725/
https://www.ncbi.nlm.nih.gov/pubmed/31164456
http://dx.doi.org/10.1634/theoncologist.2019-0294

Ejemplares similares